Scientific Due Diligence & Commercialization Strategy for Cannabinoid and Wellness Investments
Board-Level Scientific Leadership. Commercial Risk Mitigation. Scalable Product Platforms.
Who We Serve
We partner with global:
Private Equity firms evaluating cannabinoid or wellness investments
Mid-size brands ($5M–$50M revenue) scaling product portfolios
International groups entering regulated cannabinoid markets
Consumer health platforms preparing for acquisition or expansion
What We Deliver
Formulation risk assessment
Regulatory exposure mapping
IP defensibility review
Manufacturing scalability analysis
Cost structure technical validation
R&D program restructuring
Development pipeline optimization
Vendor technical audits
GPP(GMP) / QA alignment
Product platform architecture
Technology transfer oversight
Scale-up execution strategy
Scientific narrative for investors
Who We Are
We are a scientific group led by a former:
PDS - Cannabinoid – Fertin Pharma (Canada) (PMI)
Science Plan Manager – BAT Centre of Excellence
Cannabinoid IVD & PK alternative research lead
Extraction facility technical lead (11,000 sqf build & process design)
Etraction & QA manager
We provide capital protection + strategic product architecture.
Engagement Options
Innovation Portfolio Readiness Assessment (6–8 Weeks)
Structured review of scalability, governance, and EU alignment.
Strategic Advisory Support (Project or Retainer)
Executive-level support for expansion and portfolio structuring.
Investor Technical Advisory
Independent innovation/regulatory and commercialization evaluation.
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!